← FDA DRUG APPROVALS

FDA ANDA · ANDA078021

AMLODIPINE BESYLATE

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA078021
TYPE
ANDA
ORIGINAL APPROVAL
2007-07-17
LATEST ACTION
2018-03-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

AMLODIPINE BESYLATEPrescription
AMLODIPINE BESYLATE EQ 5MG BASE · TABLET · ORAL
AMLODIPINE BESYLATEPrescription
AMLODIPINE BESYLATE EQ 10MG BASE · TABLET · ORAL
AMLODIPINE BESYLATEPrescription
AMLODIPINE BESYLATE EQ 2.5MG BASE · TABLET · ORAL

Approval history

2018-03-14Labeling · Supplement 12 · standardAP
2018-03-14Labeling · Supplement 13 · standardAP
2015-09-17Labeling · Supplement 11 · standardAP
2014-09-26Labeling · Supplement 9 · standardAP
2011-12-31Labeling · Supplement 8AP
2011-08-31Labeling · Supplement 7AP
2010-06-30Labeling · Supplement 4AP
2008-10-21Labeling · Supplement 3AP
2007-07-17OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →